Clinical research jobs provider Merck Sharpe and Dohme's investigational oral mTOR medication ridaforolimus has been accepted for review by the European Medicines Agency (EMA).
The healthcare regulator has now completed the administrative validation procedure for the regulatory application of the compound, which is intended to combat metastatic soft[-]tissue or bone sarcomas.
Ridaforolimus, which was developed in a partnership between Merck Sharpe and Dohme and Ariad Pharmaceuticals, has also recently been submitted for approval by the US Food and Drug Administration.
Marty Duvall, senior vice president and general manager for the oncology franchise at Merck Global Human Health, said: "This acceptance of the EMA filing for review is an important milestone as we seek to bring forward a potential treatment option for patients with metastatic bone and soft tissue sarcomas."
Earlier this month, the pharmaceuticals company joined forces with the Serum Institute of India to develop and commercialise a new pneumococcal conjugate vaccine to be used in underprivileged nations.